Mann Bioinvest is an Isle of Man-based biotechnology advisory specialist firm chaired by notable UK investor Jim Mellon. The fund management team needed a press release to announce the launch of a new investment fund. The quality of the fund management team is critical in evaluating the likely success of a fund, so it was important in the narrative to give due weight to the chief investment officer’s track record at other major funds and his pharmaceutical industry experience. The press release highlighted the success of an earlier Mann Bio fund, as well as explaining the investment vision and key points differentiating the fund from existing biotech investment trends. The role of Jim Mellon’s reputation as a source of deal flow was significant but should not detract from the wider attractions of the investment offering. The press release was widely distributed.